Literature DB >> 32790899

Novel insights into the function of CD24: A driving force in cancer.

Peter Altevogt1,2, Marei Sammar3, Laura Hüser1,2, Glen Kristiansen4.   

Abstract

CD24 is a highly glycosylated protein with a small protein core that is linked to the plasma membrane via a glycosyl-phosphatidylinositol anchor. CD24 is primarily expressed by immune cells but is often overexpressed in human tumors. In cancer, CD24 is a regulator of cell migration, invasion and proliferation. Its expression is associated with poor prognosis and it is used as cancer stemness marker. Recently, CD24 on tumor cells was identified as a phagocytic inhibitor ("do not eat me" signal) having a suppressive role in tumor immunity via binding to Siglec-10 on macrophages. This finding is reminiscent of the demonstration that soluble CD24-Fc can dampen the immune system in autoimmune disease. In the present review, we summarize recent progress on the role of the CD24-Siglec-10 binding axis at the interface between tumor cells and the immune system, and the role of CD24 genetic polymorphisms in cancer. We describe the specific function of cytoplasmic CD24 and discuss the presence of CD24 on tumor-released extracellular vesicles. Finally, we evaluate the potential of CD24-based immunotherapy.
© 2020 UICC.

Entities:  

Keywords:  CD24; Fc fusion proteins; Siglecs; carbohydrates; extracellular vesicles; phagocytosis; selectins

Mesh:

Substances:

Year:  2020        PMID: 32790899     DOI: 10.1002/ijc.33249

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  Knock-Down of CD24 in Astrocytes Aggravates Oxyhemoglobin-Induced Hippocampal Neuron Impairment.

Authors:  Xiang-Xin Chen; Tao Tao; Sen Gao; Han Wang; Xiao-Ming Zhou; Yong-Yue Gao; Chun-Hua Hang; Wei Li
Journal:  Neurochem Res       Date:  2021-10-19       Impact factor: 3.996

2.  Suitability assessment of CD24 targeted-therapy in the cancer patients with COVID-19: Preliminary results from pan-cancer.

Authors:  Bin Wang; Jiantao Fu; Anqian Lu; Jin Yang
Journal:  J Infect       Date:  2022-05-31       Impact factor: 38.637

Review 3.  Perspective of Immunopathogenesis and Immunotherapies for Kawasaki Disease.

Authors:  Lung Chang; Horng-Woei Yang; Tang-Yu Lin; Kuender D Yang
Journal:  Front Pediatr       Date:  2021-07-19       Impact factor: 3.418

Review 4.  The intriguing roles of Siglec family members in the tumor microenvironment.

Authors:  Kui-Ying Jiang; Li-Li Qi; Fu-Biao Kang; Ling Wang
Journal:  Biomark Res       Date:  2022-04-13

Review 5.  Targeting the "Sweet Side" of Tumor with Glycan-Binding Molecules Conjugated-Nanoparticles: Implications in Cancer Therapy and Diagnosis.

Authors:  Nora Bloise; Mohammad Okkeh; Elisa Restivo; Cristina Della Pina; Livia Visai
Journal:  Nanomaterials (Basel)       Date:  2021-01-22       Impact factor: 5.076

Review 6.  Apoptosis during ZIKA Virus Infection: Too Soon or Too Late?

Authors:  Jonathan Turpin; Daed El Safadi; Grégorie Lebeau; Morgane Krejbich; Camille Chatelain; Philippe Desprès; Wildriss Viranaïcken; Pascale Krejbich-Trotot
Journal:  Int J Mol Sci       Date:  2022-01-24       Impact factor: 5.923

7.  Molecular Radiotherapy with 177Lu-Immunoliposomes Induces Cytotoxicity in Mesothelioma Cancer Stem Cells In Vitro.

Authors:  Tao Huang; Jae Sam Lee; Alexander L Klibanov; Jiang He
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

8.  Detection and Investigation of Extracellular Vesicles in Serum and Urine Supernatant of Prostate Cancer Patients.

Authors:  Samanta Salvi; Erika Bandini; Silvia Carloni; Valentina Casadio; Michela Battistelli; Sara Salucci; Ilaria Erani; Emanuela Scarpi; Roberta Gunelli; Giacomo Cicchetti; Michele Guescini; Massimiliano Bonafè; Francesco Fabbri
Journal:  Diagnostics (Basel)       Date:  2021-03-08

Review 9.  Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.

Authors:  Elena Gianchecchi; Andrea Arena; Alessandra Fierabracci
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

10.  CD24 Contributes to Treatment Effect in ABC-DLBCL Patients with R-CHOP Resistance.

Authors:  Li-Yan Qiao; Han-Bing Li; Yue Zhang; Di Shen; Peng Liu; Yi-Qun Che
Journal:  Pharmgenomics Pers Med       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.